Home > News > Headline News


Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

Fred Hutchinson Cancer Center receives $4.1 M grant to study ways to prevent metastatic breast cancer.

June 30, 2015

By Fred Hutchinson Cancer Center, Seattle: press release

Cyrus Ghajar, Ph.D., a metastatic breast cancer researcher at Fred Hutchinson Cancer Research Center, has received a $4.1 million Department of Defense Breast Cancer Research Program (BCRP) “Era of Hope” Scholar Award.

Ghajar is investigating two different paths for dealing with these dormant disseminated tumor cells: keeping them asleep and inactive, or destroying them altogether.

“Basically, we are hedging our bets. You might be able to keep these cells asleep forever, but this carries an inherent risk because you are leaving these ticking time bombs in your body. Perhaps we can mitigate this with a strong enough ‘sedative,’” he said. “But just in case, we also have ways we think will allow us to specifically get rid of them.”

According to Ghajar, the phenomenon of tumor dormancy has not been the subject of much study over the years. As a result, “we don’t really know a whole lot about these cells in terms of what puts them to sleep and what wakes them up,” he said.

Exemestane with or without Entinostat in Treating Postmenopausal Patients with Recurrent Hormone Receptor-Positive Breast Cancer

June 29, 2015

By ECOG-Acrin Cancer Research Group

Promising Phase 3 Trial E2112 for those with ER+ Resistant Disease will test Exomestane (Aromasin) plus Entinostat vs. Aromasin plus Placebo. Read more to see if you qualify!

Stanford stem cell product, delayed for more than a decade, to be tested again

June 14, 2015

By Mercury News

In its initial small trial in women with advanced breast cancer at the Stanford University School of Medicine in the mid to late '90s, patients who received aggressive high-dose chemotherapy -- followed by Weissman's "rescue" with their own purified stem cells -- significantly boosted their chances of long-term survival.

This Woman Documented Her Breast Cancer Diagnosis, And 43 Million People Responded

June 9, 2015

By The Huffington Post, Leigh Weingus

In 2012, Holley Kitchen was diagnosed with breast cancer. After being treated with a double mastectomy, chemo, radiation and hormone therapy, she thought her cancer battle was over. But in November of 2013, she was told her breast cancer returned and had spread to her spine and bones.

Kitchen now has stage 4 metastatic breast cancer, an aggressive form that spreads outside the breast. In hopes of informing people about breast cancer and everything she and other women living with breast cancer are going through, Kitchen put together a three-minute video in which she silently presents written facts while Rachel Platten's "Fight Song" plays in the background. Since she posted it to Facebook, Kitchen's video has gotten over 43 million views.

MM-302 Shows Promise in Heavily Pretreated HER2-Positive Breast Cancer

April 30, 2015

By Cancer Network

A phase I study of MM-302 had a manageable safety profile and encouraging efficacy results in a group of heavily pretreated women with HER2-positive metastatic breast cancer.

Anti-PDL1 Agent Promising in Advanced Breast Cancer

April 23, 2015

By Medscape

In patients with metastatic triple-negative breast cancer, immunotherapy with the monoclonal antibody MPDL3280A appeared to be safe, tolerable, and capable of durable clinical activity, according to results from an ongoing multicenter phase Ia study.

Palbociclib Delays Breast Cancer Progression in Phase III Trial

April 15, 2015

By Onc Live: Jason M. Broderick and Silas Inman

The PALOMA-3 trial examining a palbociclib regimen in HR+/HER2- breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival (PFS). The results were announced by Pfizer, the company developing palbociclib, which noted that these are the first randomized phase III data reported for the CDK 4/6 inhibitor.

MBCN NOTE: This is another step closer to having Ibrance approved for 2nd and  3rd line treatment of ER+ resistant disease. Currently Ibrance is approved only for initial treatment.

Top Breast and Ovarian Cancer Research Findings for the Past Year

March 13, 2015

By OncLive

These findings are among the 2014 highlights that Tripathy reviewed in an overview that was the annual feature of the Miami Breast Cancer Conference Feb. 26-Marc -

Breast Cancer Cocktail Buys More Than a Year of Life

February 24, 2015

By Maggie Fox and Maren Shapiro

A cocktail of three breast cancer drugs buys patients an extra 16 months of life — a good news story so unusual, doctors have rushed to make it standard therapy, researchers said Wednesday.

Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan

February 13, 2015

By Journal of Medical Case Reports 2015, 9:5

Pegylated irinotecan NKTR-102 is a topoisomerase I inhibitor-polymer conjugate. This new formulation of irinotecan has been evaluated in a phase II clinical trial and is showing remarkable activity.
 1 2 3 >  Last ›